Clinical Trials
35 trialsNCT06137118 2026-05-27
SYRUS
AstraZeneca
Phase 1/2 Recruiting
NCT07354074 2026-05-26
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
Phase 2 Recruiting
NCT07167381 2026-05-19
xDRIVE for Florida-based Cancer Patients
First Ascent Biomedical Inc.
Phase NA Recruiting
NCT05748171 2026-05-14
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
Phase 2 Recruiting
NCT07007312 2026-05-12
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Phase 3 Recruiting
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT04256317 2026-04-30
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
NCT06578247 2026-04-30
QuANTUM-WILD
Daiichi Sankyo
Phase 3 Recruiting
NCT07556757 2026-04-29
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
ImmunityBio, Inc.
Phase 1 Recruiting
NCT05475925 2026-04-17
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
Phase 1/2 Recruiting
NCT03934372 2026-04-16
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
NCT07504458 2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3 Recruiting
NCT04329728 2026-04-15
OPAL
AVM Biotechnology Inc
Phase 1/2 Recruiting
NCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT06001788 2026-04-14
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
NCT07284433 2026-04-02
QUADvance
AvenCell Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06533579 2026-03-30
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT04065399 2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2 Recruiting
NCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05589896 2026-02-24
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Phase 1/2 Recruiting
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT02966756 2025-12-24
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AbbVie
Phase 2 Recruiting
NCT03342144 2025-12-08
VeRVe
AbbVie
Recruiting
NCT06824168 2025-12-04
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Daiichi Sankyo
Phase 2 Recruiting
NCT06549790 2025-10-31
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences
Phase 1 Recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT05673057 2025-09-30
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Molecular Partners AG
Phase 1/2 Recruiting
NCT06501196 2025-09-24
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
Phase 1 Recruiting
NCT05282108 2025-03-26
CARCML
Hikma Pharmaceuticals LLC
Recruiting
NCT04466059 2024-12-17
BELUGA
Munich Leukemia Laboratory
Recruiting
NCT05046444 2024-12-17
SIRIUS
Munich Leukemia Laboratory
Recruiting
NCT06034275 2024-11-15
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.
Phase 1 Recruiting
NCT04014374 2024-07-24
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Kyowa Kirin Co., Ltd.
Recruiting
NCT05635266 2024-05-07
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
Recruiting
NCT06006403 2023-08-30
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting